One-year follow-up of transgene expression by integrase-defective lentiviral vectors and their therapeutic potential in spinocerebellar ataxia model mice

Gene Therapy

Volumn 21, Issue 9, 2014, Pages 820-827

  Saida, H ^a   Matsuzaki, Y ^a   Takayama, K ^a   Iizuka, A ^a   Konno, A ^a   Yanagi, S ^b   Hirai, H ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; ATAXIN 3; GREEN FLUORESCENT PROTEIN; INTEGRASE; INTEGRASE DEFECTIVE LENTIVIRAL VECTOR; LENTIVIRUS VECTOR; MESSENGER RNA; UNCLASSIFIED DRUG; VALINE; CRAG PROTEIN, MOUSE; GUANOSINE TRIPHOSPHATASE;

ALU SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATAXIA; COMPARATIVE STUDY; CONFOCAL MICROSCOPY; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LONG TERMINAL REPEAT; MOUSE; NONHUMAN; NUCLEAR IMPORT; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ROTAROD TEST; SPATIOTEMPORAL ANALYSIS; SPINOCEREBELLAR ATAXIA; TRANSGENE; VIRAL GENE THERAPY; VIRUS GENOME; WESTERN BLOTTING; WILD TYPE; ADMINISTRATION AND DOSAGE; ANIMAL; CEREBELLUM; DISEASE MODEL; GENE VECTOR; GENETICS; HEK293 CELL LINE; HELA CELL LINE; LENTIVIRINAE; METABOLISM; MUTATION; SIGNAL TRANSDUCTION; SPINOCEREBELLAR ATAXIAS; VIROLOGY;

EPICOCCUM; MUS;

ANIMALS; CEREBELLUM; DISEASE MODELS, ANIMAL; FOLLOW-UP STUDIES; GENETIC VECTORS; GTP PHOSPHOHYDROLASES; HEK293 CELLS; HELA CELLS; HUMANS; INTEGRASES; LENTIVIRUS; MICE; MUTATION; ROTAROD PERFORMANCE TEST; SIGNAL TRANSDUCTION; SPINOCEREBELLAR ATAXIAS; TRANSGENES;

EID: 84927025052     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2014.60     Document Type: Article

References (45)

1. Lever AM, Strappe PM, Zhao J. Lentiviral vectors. J Biomed Sci 2004; 11: 439-449.
2. Apolonia L, Waddington SN, Fernandes C, Ward NJ, Bouma G, Blundell MP et al. Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol Ther 2007; 15: 1947-1954.
3. Kulkosky J, Skalka AM. Molecular mechanism of retroviral DNA integration. Pharmacol Ther 1994; 61: 185-203.
4. Hindmarsh P, Leis J. Retroviral DNA integration. Microbiol Mol Biol Rev 1999; 63: 836-843; table of contents.
5. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-Associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419.
6. Li Z, Dullmann J, Schiedlmeier B, Schmidt M, von Kalle C, Meyer J et al. Murine leukemia induced by retroviral gene marking. Science 2002; 296: 497.
7. Matrai J, Chuah MK, VandenDriessche T. Recent advances in lentiviral vector development and applications. Mol Ther 2010; 18: 477-490.
8. Banasik MB, McCray Jr. PB. Integrase-defective lentiviral vectors: progress and applications. Gene Therapy 2010; 17: 150-157.
9. Bayer M, Kantor B, Cockrell A, Ma H, Zeithaml B, Li X et al. A large U3 deletion causes increased in vivo expression from a nonintegrating lentiviral vector. Mol Ther 2008; 16: 1968-1976.
10. Lombardo A, Genovese P, Beausejour CM, Colleoni S, Lee YL, Kim KA et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol 2007; 25: 1298-1306.
11. Nightingale SJ, Hollis RP, Pepper KA, Petersen D, Yu XJ, Yang C et al. Transient gene expression by nonintegrating lentiviral vectors. Mol Ther 2006; 13: 1121-1132.
12. Philippe S, Sarkis C, Barkats M, Mammeri H, Ladroue C, Petit C et al. Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci USA 2006; 103: 17684-17689.
13. Saenz DT, Loewen N, Peretz M, Whitwam T, Barraza R, Howell KG et al. Unintegrated lentivirus DNA persistence and accessibility to expression in nondividing cells: analysis with class I integrase mutants. J Virol 2004; 78: 2906-2920.
14. Yanez-Munoz RJ, Balaggan KS, MacNeil A, Howe SJ, Schmidt M, Smith AJ et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 2006; 12: 348-353.
15. Qin Q, Inatome R, Hotta A, Kojima M, Yamamura H, Hirai H et al. A novel GTPase, CRAG, mediates promyelocytic leukemia protein-Associated nuclear body formation and degradation of expanded polyglutamine protein. J Cell Biol 2006; 172: 497-504.
16. Torashima T, Koyama C, Iizuka A, Mitsumura K, Takayama K, Yanagi S et al. Lentivector-mediated rescue from cerebellar ataxia in a mouse model of spinocerebellar ataxia. EMBO Rep 2008; 9: 393-399.
17. Leavitt AD, Robles G, Alesandro N, Varmus HE. Human immunodeficiency virus type 1 integrase mutants retain in vitro integrase activity yet fail to integrate viral DNA efficiently during infection. J Virol 1996; 70: 721-728.
18. Vatakis DN, Kim S, Kim N, Chow SA, Zack JA. Human immunodeficiency virus integration efficiency and site selection in quiescent CD4+ T cells. J Virol 2009; 83: 6222-6233.
19. Nakajima N, Lu R, Engelman A. Human immunodeficiency virus type 1 replication in the absence of integrase-mediated dna recombination: definition of permissive and nonpermissive T-cell lines. J Virol 2001; 75: 7944-7955.
20. Sawada Y, Kajiwara G, Iizuka A, Takayama K, Shuvaev AN, Koyama C et al. High transgene expression by lentiviral vectors causes maldevelopment of Purkinje cells in vivo. Cerebellum 2010; 9: 291-302.
21. Liu B, Wang S, Brenner M, Paton JF, Kasparov S. Enhancement of cell-specific transgene expression from a Tet-Off regulatory system using a transcriptional amplification strategy in the rat brain. J Gene Med 2008; 10: 583-592.
22. Hioki H, Kuramoto E, Konno M, Kameda H, Takahashi Y, Nakano T et al. High-level transgene expression in neurons by lentivirus with Tet-Off system. Neurosci Res 2009; 63: 149-154.
23. Kobayashi K, Yasuhara T, Agari T, Muraoka K, Kameda M, Ji Yuan W et al. Control of dopamine-secretion by Tet-Off system in an in vivo model of parkinsonian rat. Brain Res 2006; 1102: 1-11.
24. Sloan B, Scheinfeld N. The use and safety of doxycycline hyclate and other second-generation tetracyclines. Expert Opin Drug Saf 2008; 7: 571-577.
25. Vandenberghe LH, Auricchio A. Novel adeno-Associated viral vectors for retinal gene therapy. Gene Therapy 2012; 19: 162-168.
26. Weinberg MS, Samulski RJ, McCown TJ. Adeno-Associated virus (AAV) gene therapy for neurological disease. Neuropharmacology 2013; 69: 82-88.
27. Lentz TB, Gray SJ, Samulski RJ. Viral vectors for gene delivery to the central nervous system. Neurobiol Dis 2012; 48: 179-188.
28. Stieger K, Schroeder J, Provost N, Mendes-Madeira A, Belbellaa B, Le Meur G et al. Detection of intact rAAV particles up to 6 years after successful gene transfer in the retina of dogs and primates. Mol Ther 2009; 17: 516-523.
29. Niemeyer GP, Herzog RW, Mount J, Arruda VR, Tillson DM, Hathcock J et al. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood 2009; 113: 797-806.
30. Terashima T, Miwa A, Kanegae Y, Saito I, Okado H. Retrograde and anterograde labeling of cerebellar afferent projection by the injection of recombinant adenoviral vectors into the mouse cerebellar cortex. Anat Embryol 1997; 196: 363-382.
31. Iino M, Goto K, Kakegawa W, Okado H, Sudo M, Ishiuchi S et al. Glia-synapse interaction through Ca2+-permeable AMPA receptors in Bergmann glia. Science 2001; 292: 926-929.
32. Duale H, Kasparov S, Paton JF, Teschemacher AG. Differences in transductional tropism of adenoviral and lentiviral vectors in the rat brainstem. Exp Physiol 2005; 90: 71-78.
33. Hartman ZC, Appledorn DM, Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res 2008; 132: 1-14.
34. Johnson WG. Late-onset neurodegenerative diseases-the role of protein insolubility. J Anat 2000; 196 (Part 4): 609-616.
35. Nagai Y, Popiel HA. Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis. Curr Pharm Des 2008; 14: 3267-3279.
36. Seidel K, Siswanto S, Brunt ER, den Dunnen W, Korf HW, Rub U. Brain pathology of spinocerebellar ataxias. Acta Neuropathol 2012; 124: 1-21.
37. Williams A, Jahreiss L, Sarkar S, Saiki S, Menzies FM, Ravikumar B et al. Aggregateprone proteins are cleared from the cytosol by autophagy: therapeutic implications. Curr Top Dev Biol 2006; 76: 89-101.
38. Hegde AN, Upadhya SC. Role of ubiquitin-proteasome-mediated proteolysis in nervous system disease. Biochim Biophys Acta 2011; 1809: 128-140.
39. Takalo M, Salminen A, Soininen H, Hiltunen M, Haapasalo A. Protein aggregation and degradation mechanisms in neurodegenerative diseases. Am J Neurodegen Dis 2013; 2: 1-14.
40. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991; 108: 193-199.
41. Torashima T, Yamada N, Itoh M, Yamamoto A, Hirai H. Exposure of lentiviral vectors to subneutral pH shifts the tropism from Purkinje cell to Bergmann glia. Eur J Neurosci 2006; 24: 371-380.
42. Brussel A, Delelis O, Sonigo P. Alu-LTR real-time nested PCR assay for quantifying integrated HIV-1 DNA. Methods Mol Biol 2005; 304: 139-154.
43. Kass DH, Raynor ME, Williams TM. Evolutionary history of B1 retroposons in the genus Mus. J Mol Evol 2000; 51: 256-264.
44. Nelson DL, Ledbetter SA, Corbo L, Victoria MF, Ramirez-Solis R, Webster TD et al. Alu polymerase chain reaction: a method for rapid isolation of human-specific sequences from complex DNA sources. Proc Natl Acad Sci USA 1989; 86: 6686-6690.
45. Waterston RH, Lindblad-Toh K, Birney E, Rogers J, Abril JF, Agarwal P et al. Initial sequencing and comparative analysis of the mouse genome. Nature 2002; 420: 520-562.